Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
114C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration----[3] 13, 96, 97
2ADMINISTRATION----[1] 19
3Administration Kit----[1] 19
4Administration of a high dose of desipramine[1] Desipramine[2] D00812 ,
D07791 		[2] SLC6A2,
SLC6A4 💬		[2] Serotonergic synapse, Synaptic vesicle cycle 💬[1] 156
5Administration of a low dose of desipramine[1] Desipramine[2] D00812 ,
D07791 		[2] SLC6A2,
SLC6A4 💬		[2] Serotonergic synapse, Synaptic vesicle cycle 💬[1] 156
6Administration of an ACE-inhibitor or not----[1] 210
7Administration of Cimzia®[1] Certolizumab pegol[1] D03441 [1] TNF 💬[67] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬[1] 46
8Administration of drug (Interferon-gamma 1-b) subcutaneously----[1] 65
9Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil[4] Methylprednisolone,
Mycophenolate mofetil,
Mycophenolic acid,
Prednisone		[11] D00407 ,
D00473 ,
D00751 ,
D00752 ,
D00979 ,
D05000 ,
D05001 ,
D05002 ,
D05094 ,
D05095 ,
D05096 		[3] IMPDH1,
IMPDH2,
NR3C1 💬		[4] Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Purine metabolism 💬[1] 49
10Administration of methylprednisolone, paracetamol and dexchlorpheniramine[3] Acetaminophen,
Dexchlorpheniramine,
Methylprednisolone		[8] D00217 ,
D00407 ,
D00751 ,
D00979 ,
D05000 ,
D05001 ,
D05002 ,
D07803 		[4] HRH1,
NR3C1,
PTGS1,
PTGS2 💬		[26] Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Calcium signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬[1] 49
11Administration of rituximab and methylprednisolone[2] Methylprednisolone,
Rituximab		[7] D00407 ,
D00751 ,
D00979 ,
D02994 ,
D05000 ,
D05001 ,
D05002 		[2] MS4A1,
NR3C1 💬		[2] Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬[1] 51
12Administration of stable isotope-labelled leucine-[1] Leucine[1] D00030 --[1] 6
13Avandia administration for 6-12 weeks----[1] 265
14Behavioral: Administration of probiotic (L. rhamnosus and L. acidophilus)[1] Lactobacillus acidophilus[1] D04349 --[1] 97
15Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)[1] Human immunoglobulin G---[1] 14
16Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)[1] Human immunoglobulin G---[1] 14
17Bosentan administration[1] Bosentan[2] D01227 ,
D07538 		[2] EDNRA,
EDNRB 💬		[9] Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬[1] 86
18CS1 Administration----[1] 86
19Docosahexaenoic acid administration: 50 mg/kg/day during 12 months[1] Doconexent---[1] 299
20Experimental: CRH administration----[2] 72, 78
21Experimental: GLP1-RA (exenatide) administration[1] Exenatide[1] D04121 [1] GLP1R 💬[3] Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬[2] 72, 78
22Growth hormone administration for 6 months[1] Somatotropin[1] D02691 [1] GHR 💬[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬[1] 78
23Human normal 10% immunoglobulin for intravenous administration[1] Human immunoglobulin G---[1] 14
24Human normal 10% immunoglobulin for intravenous administrationn[1] Human immunoglobulin G---[1] 14
25Human normal immunoglobulin for intravenous (IV) administration[1] Human immunoglobulin G---[1] 51
26Human normal immunoglobulin for intravenous administration[1] Human immunoglobulin G---[3] 14, 51, 65
27Human normal immunoglobulin for subcutaneous administration[1] Human immunoglobulin G---[2] 51, 65
28Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)[1] Human immunoglobulin G---[1] 65
29Intrathecal administration of autologous MSC-NP----[1] 13
30Intravenous administration of 1 million of MSC----[1] 2
31Intravenous administration of 2 million of MSC----[1] 2
32Intravenous administration of 4 million of MSC----[1] 2
33Intravenous administration of ferric carboxymaltose[1] Ferric carboxymaltose[1] D08920 --[1] 86
34IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)----[1] 285
35Levodopa (drug), intraduodenal administration[1] Levodopa[1] D00059 [5] DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		[11] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬[1] 6
36Levodopa and carbidopa solution for SC administration[2] Carbidopa,
Levodopa		[2] D00059 ,
D00558 		[6] DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		[16] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬[1] 6
37Low-dose IL-2 administration[1] Human interleukin-2---[1] 96
38Methotrexate + biologic administration[1] Methotrexate[2] D00142 ,
D02115 		[2] DHFR,
DHFR2 💬		[5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬[1] 46
39Methotrexate + salazopyrine + hydroxychloroquine administration[2] Hydroxychloroquine,
Methotrexate		[3] D00142 ,
D02115 ,
D08050 		[2] DHFR,
DHFR2 💬		[5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬[1] 46
40Methotrexate(MTX) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol[1] Methotrexate[2] D00142 ,
D02115 		[2] DHFR,
DHFR2 💬		[5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬[1] 46
41Methotrexate(MTX) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol.[1] Methotrexate[2] D00142 ,
D02115 		[2] DHFR,
DHFR2 💬		[5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬[1] 46
42NIRS after bosentan administration[1] Bosentan[2] D01227 ,
D07538 		[2] EDNRA,
EDNRB 💬		[9] Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬[1] 13
43Obinutuzumab administration[1] Obinutuzumab[1] D09321 [1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 49
44Other: Questionnaire Administration----[4] 16, 34, 51, 298
45Other: Tobramycin time of administration[1] Tobramycin[2] D00063 ,
D02542 		--[1] 299
46QR-313 Gel for Topical (Cutaneous) Administration----[1] 36
47RAAV1-CMV-GAA (study agent) Administration----[1] 256
48Routine steroid administration group----[1] 85
49Semi continuous intra-oral administration of LD/CD----[1] 6
50Subcutanious administration----[1] 46
51Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus----[1] 90
52TCD after bosentan administration[1] Bosentan[2] D01227 ,
D07538 		[2] EDNRA,
EDNRB 💬		[9] Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬[1] 13